Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland

BMC Cardiovascular Disorders

Agnieszka Machowska-Majchrzak³  Marta Swiech¹  Michal Skrzypek²  Krystyna Pierzchala³  Beata Labuz-Roszak³ 

[1] Laboratory of Genomic Medicine, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland;Department of Biostatistics, Faculty of Public Health, Medical University of Silesia, Katowice, Poland;Department of Neurology, Medical University of Silesia, 3-go Maja 13/15, Zabrze, 41-800, Poland

关键词: Acetylsalicylic acid;    Antiplatelet drugs;    Oral anticoagulant drugs;    Preventive medicine;    Public health;    Elderly;    Epidemiology;   

Others  :  858017
DOI  :  10.1186/1471-2261-12-98

 received in 2012-04-03, accepted in 2012-10-26,  发布年份 2012

【 摘 要 】

Background

In Poland, the prevalence of cardiovascular diseases is increasing. This might be associated with the constantly growing proportion of elderly people and inappropriate cardiovascular prevention. This study aimed to evaluate the frequency of use of oral antiplatelet (OAP) and oral anticoagulant (OAC) drugs among older people in Poland and to assess their association with cardiovascular risk factors.

Methods

The study was based on data collected during the implementation of a multicentre, publicly funded research project called PolSenior.

Results

The study group consisted of 4,979 people with the average age of 79.35 ± 8.69 years. Among them, 1,787 people (35.9%) used at least one drug in the prevention of cardiovascular diseases. OAPs were used regularly by 1,648 (33.1%) elderly people and OACs were used by 165 elderly people (3.3%). Acetylsalicylic acid was used by 32.2% of elderly people. Use of drugs significantly depended on age (p < 0.01), sex (p < 0.01), place of residence (p < 0.001), level of education (p < 0.0001) and personal income (p < 0.0001). Among all the respondents treated with OAPs, therapy was applied as secondary cardiovascular prevention in 717 respondents (43.5%), and as primary prevention in 705 respondents (42.8%). Among the respondents treated with OACs, 117 (71%) elderly people had a history of atrial fibrillation. Secondary cardiovascular prevention should be considered in a further 482 respondents (15.1% of untreated elderly people), and primary cardiovascular prevention in 1,447 respondents (45.3%).

Conclusions

Our study is the first to determine the frequency of use of OAP and OAC drugs among elderly people in Poland in relation to cardiovascular risk factors. The most commonly used drug for cardiovascular prevention is acetylsalicylic acid, but it appears that it is used too rarely in high-risk patients. Educational programs should be developed among general practitioners concerning current recommendations for pharmacological cardiovascular prevention.

【 授权许可】

   
2012 Labuz-Roszak et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y: Heart disease and stroke statistics – 2008 update: a report from American Heart Association Statistics Committee and stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
• [2]Kesteloot H, Sans S, Kromhout D: Dynamics of cardiovascular and allcause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J 2006, 27:107-113.
• [3]Tunstall-Pedoe H, Kulaasma K, Mahonen M, Tolonen H, Ruokokoski E: Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999, 353:1547-1557.
• [4]Varon D, Spectre G: Antiplatelet agents. Hematology 2009, 1:267-272.
• [5]Jack DB: One hundred years of aspirin. Lancet 1997, 350:437-439.
• [6]Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971, 231:232-235.
• [7]Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
• [8]Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
• [9]Shulga O, Bornstein N: Antiplatelets in secondary stroke prevention. Front Neurol 2011, 2:1-6.
• [10]Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119(Suppl):8-21.
• [11]Bledowski P, Mossakowska M, Chudek J, Grodzicki T, Milewicz A, Szybalska A, Wieczorowska-Tobis K, Wiecek A, Bartoszek A, Dabrowski A, Zdrojewski T: Medical, psychological and socioeconomic aspects of aging in Poland. Assumptions and objectives of the PolSenior project. Exp Gerontol 2011, 46:1003-1009.
• [12]Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, on behalf of the SCORE project group: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
• [13]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
• [14]Polish Central Statistical Office 2009. http://www.stat.gov.pl/gus Accessed 20 December 2011
• [15]Asberg S, Henriksson KM, Farahmand B: Ischemic stroke and secondary prevention in clinical practice. Stroke 2010, 41:1338-1342.
• [16]Wei JW, Wang JG, Huang Y, Liu M, Wu Y, Wong LK, Cheng Y, Xu E, Yang Q, Arima H, Heeley EL, Anderson CS, for the ChinaQUEST Investigators: Secondary prevention of ischaemic stroke in urban China. Stroke 2010, 41:967-974.
• [17]Wachtel TM, Kucia AM, Greenhill JA: Secondary prevention for acute coronary syndrome in rural South Australia: Are drugs best? What about the rest? Rural and Remote Health 2008, 8:967. (Online) http://www.rrh.org.au Accessed 5 October 2011
• [18]Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM: Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007, 32:403-407.
• [19]Verro P, Gorelick PB, Nguyen D: Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA. Stroke 2008, 39:1358-1363.
• [20]Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673.
• [21]http://www.pulsmedycyny.com.pl/index/archiwum/7350,udar,m%C3%B3zgu,%C5%82%C4%85czenie.htm Accessed 25 October 2011
• [22]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte W, Weissberg P, Wood D, Yarnell J, Zamorano JL: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts): European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28:2375-2414.
• [23]Gao R, Li X: Risk assessment and aspirin use in Asian and Western populations. Vasc Health Risk Manag 2010, 6:943-956.
• [24]Camm AJ, Kirchhof P, Lip GY, Schotten U, Savalieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kohl P, Le Heuzey JY, Ponikowski P, Rutten F: Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
• [25]Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS: Aspirin for primary prevention of cardiovascular events in people with diabetes. JACC 2010, 55:2878-2886.
• [26]Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Mathews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, Mac-Walter R: The prevention of progression of arterial disease and diabetes {POPADAD} trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease [abstract]. BMJ 2008, 337:s1840.
• [27]Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators: Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2214.
• [28]Leung WY, So W, Steward D, Lui A, Tong PC, Ko GT, Ma RC, Chan FK, Yang X, Chiang S, Chan JC: Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients – a longitudinal observational study. Cardiovasc Diabetol 2009, 8:57-67. BioMed Central Full Text
• [29]Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. Am Heart J 2011, 162:115-124.